Characteristics of Hypophosphatasia in Adult Patients in Rheumatology and Their Value in Developing an Algorithm to HPP-diagnosis - the COHIR Multi-center Study
NCT ID: NCT06574282
Last Updated: 2025-02-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
720 participants
OBSERVATIONAL
2024-08-25
2027-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characteristics of Hypophosphatasia in Adult Patients in Rheumatology
NCT06161142
Prospective, Longitudinal, Observational Registry of Adult Patients With Hypophosphatasia (REG-HYPO)
NCT05596539
Clinical Diagnosis of Acute Porphyria
NCT01568554
APOL1 Genotyping CTA Clinical Performance Study
NCT06839833
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease
NCT01039987
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
HPP =Hypophosphatasia COHIR ="Characteristics of Hypophosphatasia in Adult Patients in Rheumatology" ALPL =Alkaline Phosphatase
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Persistant hypophosphatasemia
Second alkaline phosphatase measurement
(1-4 weeks after the 1st measurement)
Transient hypophosphatasemia (Control group without hypophosphatasia)
Second alkaline phosphatase measurement
(1-4 weeks after the 1st measurement)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Second alkaline phosphatase measurement
(1-4 weeks after the 1st measurement)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 18 years
* Clinical suspicion of hypophosphatasia
* Evidence of an abnormal ALP (ALP below LLN) within the clinical routine screening
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Bonn
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Valentin Schäfer
Univ.-Prof. Dr. med. MuDr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Valentin S. Schäfer, Univ.-Prof. Dr. med. MUDr.
Role: PRINCIPAL_INVESTIGATOR
University Hospital of Bonn
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinic of Internal Medicine III, Department of Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn
Bonn, North Rhine-Westphali, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MED2-202002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.